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Available online 13 December 2011Abstract Bone marrow-derived mesenchymal stem cells (BMSCs) have shown great promise for ischemic tissue repair.
However, poor viability of transplanted BMSCs within ischemic tissues has limited their therapeutic potential. Apelin, an
endogenous peptide, whose level is elevated following ischemia, has been shown to enhance survival of cardiomyocytes and
neuronal cells during ischemia. We hypothesized that apelin-13 protects BMSCs from apoptotic death. In this paper we
determined the potential mechanism of apelin-13 effects using cultured BMSCs from adult rats. Apoptosis was induced by
the specific apoptotic insult serum deprivation (SD) for up to 36 h. Apoptotic cell death was measured using
immunostaining and Western blotting in the presence and absence of apelin-13 (0.1 to 5.0 nM) co-applied during SD exposure.
SD-induced apoptosis was significantly reduced by apelin-13 in a concentration-dependent manner. SD-induced mitochondrial
depolarization, cytochrome c release, and caspase-3 activation were largely prevented by apelin-13. The apelin-13
anti-apoptotic effects were blocked by inhibiting the MAPK/ERK1/2 and PI3K/Akt signaling pathways. Taken together, our
findings indicate that apelin-13 is a survival factor for BMSCs and its anti-apoptotic property may prove to be of therapeutic
significance in terms of exploiting BMSC-based transplantation therapy.
© 2012 Elsevier B.V. All rights reserved.Introduction
Bone marrow-derived mesenchymal stem cells (BMSCs) are
self-renewing progenitor cells that differentiate into osteo-
blasts, chondrocytes, astrocytes, neurons, skeletal muscle
cells, and cardiomyocytes in vitro and in vivo (Pereira
et al., 1995; Azizi et al., 1998). Besides their differentiating⁎ Corresponding author at: 101 Woodruff Circle, Department of
Anesthesiology, Emory University School of Medicine, Atlanta, GA
30322, USA.
E-mail address: lwei7@emory.edu (L. Wei).
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doi:10.1016/j.scr.2011.12.004potentials, autologous BMSCs can be isolated from bone mar-
row and expanded, which makes BMSCs a conceivable source
of stem cells for repairing damaged tissues. So far, BMSCs
have been tested in several animal brain and heart ischemia
models and have shown beneficial effects by promoting tis-
sue repair and functional recovery (Li et al., 2001; Zubko
and Frishman, 2009; Hu et al., 2008; Barry and Murphy,
2004). Previous reports have shown that transplanted stem
cells including BMSCs do not survive well within diseased tis-
sues (Geng, 2003). For instance, after injection into the left
ventricle of immunodeficient adult CB17 SCID/beige mice
that are deficient in B- and T-cells, more than 99% of injected
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sult provides a piece of compelling evidence that transplanted
BMSCs are unlikely eliminated by cells in the immune system,
but die due to other mechanisms. Evidence suggests that
transplanted cells die from apoptosis (Geng, 2003; Zhang et
al., 2001), therefore strategies that enhance tolerance to ap-
optotic insults should have significant impacts on improving
the efficiency of BMSC transplantation therapy.
Apelin is a natural ligand for an orphan G protein coupled
receptor, APJ (putative receptor protein related to the
angiotensin receptor AT1) (O'Dowd et al., 1993), which had
previously been identified by the Human Genome Project in
1993 (O'Dowd et al., 1993; Falcao-Pires and Leite-Moreira,
2005). Apelin is derived from a 77 amino acid length preproa-
pelin that can be cleaved into active apelin containing 13, 17
or 36 amino acids by angiotensin-converting enzymes. The
13C-terminal amino acids are completely conserved across
all species (Lee et al., 2000). Moreover, apelin-13 invariably
exhibits greater degrees of biological potency (Simpkin
et al., 2007). The apelin/APJ system distributes over many
tissues, suggesting that they might play broad roles in physi-
ology and pathophysiology. Current data shows that apelin
is involved in the regulation of cardiovascular, gastrointesti-
nal, and immune functions, as well as in bone physiology,
fluid homeostasis, and cardiovascular system development
(Kleinz and Davenport, 2005; Masri et al., 2005). Apelin has
been shown to suppress apoptosis in osteoblastic cell line
MC3T3-E1 and human osteoblasts via the APJ/PI3K/Akt sig-
naling pathway (Xie et al., 2000; Tang et al., 2007). Howev-
er, there has been no report about the effect of apelin on
the viability of BMSCs.
Serum deprivation (SD) has been widely used as a typical
apoptotic insult to a variety of cell types and is regarded
as an insult that mimics a major ischemic component
in vivo (Behrens et al., 1996; Tsubokawa et al., 2010;
Chauvier et al., 2005). SD has been shown to induce
apoptosis in BMSCs through the mitochondrial pathway
(Tatemoto et al., 1998). The present investigation employed
this apoptotic model to test the protective effect of apelin-
13 on BMSCs. Reactive oxygen species (ROS) generation, mi-
tochondrial depolarization, cytochrome c release, and cas-
pase activation play important roles in the SD-induced
neuronal apoptosis (Chauvier et al., 2005). Inhibited PI3K
and increased extracellular signal-regulated MAPK (extracel-
lular regulated kinases, ERK1/2) have been linked to SD-
induced neuronal apoptosis (Chang et al., 2004). Our recent
work shows that apelin-13 is protective against SD- and
ischemia-induced cell death in cortical neurons and cardio-
myocytes via the mechanism of regulating the ERK1/2 and
Akt phosphorylation (Zeng et al., 2009, 2010). Apelin-13
treatment prevented the loss of mitochondrial membrane
potential during SD treatment. Moreover, apelin-13 reduced
the ROS generation and the cytochrome c release from mito-
chondria to cytoplasm as well as activation of caspase-3.
These results indicate that apelin protects cells via multiple
mechanisms (Zeng et al., 2009, 2010). Whether apelin-13
has similar protective effects on undifferentiated stem
cells or progenitor cells has not been explored. The present
investigation tested the hypothesis that apelin-13 could pro-
tect BMSCs from apoptosis by mitochondrial protection me-
diated by MAPK/ERK1/2 and PI3K/Akt signaling pathways.
Data from this investigation may be useful for promotingsurvival of transplanted BMSCs in ischemic tissue, which
will enhance the efficacy of cell therapy.
Results
Expression of APJ receptor in BMSCs
Prior to exploring the protective effects of apelin-13 in rat
BMSCs, we performed RT-PCR, immunostaining, and Western
blotting to examine the mRNA and protein levels of APJ in
rat BMSCs. RT-PCR detected expression of APJ mRNA in
BMSCs, with confirmation of primer specificity indicated by
the signal in PcDNA3.1+/APJ HEK293 cells but not in control
HEK293 cells (Fig. 1a). Expression of APJ in rat BMSCs was
detected using Immunofluorescence CD90 and APJ staining
in BMSCs (Fig. 1b). APJ was confirmed by Western blot anal-
ysis (Fig. 1c). APJ expression was not changed by serum
deprivation and apelin-13 treatment (Fig. 1c).
Effect of apelin-13 on BMSC viability
Previously, whether apelin-13 was toxic to BMSCs had not
been addressed. We examined the active form of apelin,
apelin-13, for its effect on BMSC viability. Trypan blue assay
indicated that apelin-13 up to 5 nM had no adverse effect on
the viability of BMSCs (Fig. 2a). This is a concentration range
with which apelin-13 show neuroprotective effect in cortical
neurons (Zeng et al., 2010).
Apelin-13 protected BMSCs from SD-Induced
Apoptosis
Hoechst 33342 and trypan blue staining was applied to de-
tect the SD-induced morphological changes and apoptosis
in rat BMSCs. BMSCs were exposed to serum free medium
with increasing concentrations of apelin-13 (0.1 to 5 nM)
for 36 h. This concentration range was selected based on
our previous work on the protective effect of apelin-13 on
cortical cultures (Zeng et al., 2010). After SD treatment,
cell shrinkage and nuclear condensation were obvious and
some cells were fragmented (Fig. 2b). Injured cells failed
to exclude trypan blue out, so they became trypan blue pos-
itive. SD caused about 50% cell death in trypan blue assay.
Co-applied apelin-13 showed a concentration-dependent ef-
fect of reducing SD-induced cell death. Apelin-13 at 0.5 and
5 nM significantly attenuated the number of trypan blue pos-
itive cells (Fig. 2c). Since the cell death assay was taking
place for several hours, we measured cell proliferation ac-
tivity that might interfere with the cell death assay. In the
presence of 5 nM apelin-13 and proliferation marker BrdU,
proliferative activity of BrdU-positive BMSCs did not
show significant changes during 24-h apelin-13 treatment
(Figs. 2e and f).
To further evaluate the effect of apelin-13 on cell death,
TUNEL staining was used to detect DNA fragmentation and
cell death in SD-treated BMSCs with and without apelin-13
treatment. The 36-h SD insult induced 60% cell death among
BMSCs, co-applied apelin-13 (5 nM) significantly increased
the survival of BMSCs under the SD condition; about 40% cell
death was blocked by the apelin-13 treatment (Fig. 2d). In a
Figure 1 Expression of APJ receptor in rat BMSCs. RT-PCR, immunohistochemistry and Western blotting was applied to confirm expres-
sion of the apelin receptor APJ in rat BMSCs. a. RT-PCR detectedmRNA expression of APJ in rat BMSCs. APJ primer specificity was verified by
RT-PCR detection of APJ mRNA expression in human HEK293 cells as a negative control and a rat APJ-expression plasmid (pcDNA3.1+/APJ)
used as a positive PCR control. b. Detection of APJ protein expression in rat BMSCs with an anti-APJ polyclonal antibody and immunoima-
ging. BMSCs were co-labeled with a PE-conjugated anti-rat CD90 antibody (red), and Hoechst 33342 nuclear label (blue) for total cells. An-
tibody reactivity was verified by detection of APJ (green) expression in stably transfected HEK293 cells (HEK293-APJ) but not in wild-type
HEK293 cells. Scale bar=50 μm. c.Western blot analysis showed APJ expression in BMSCs. The APJ level was not affected by treatment with
serum deprivation (SD) or SD plus apelin-13 (5 nM). All experiments were repeated at least 3 times.
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13 did not show significant protection in MTT assays although a
trend of reducing OGD-induced cell death was seen. For exam-
ple, cell survival ratewas 26.6% and 18.7% after 24-h OGDwith
and without co-applied 5 nM apelin-13 (n=3, P=0.07).Protective effect of apelin on mitochondria
TMRM is a lipophilic potentiometric dye which partitions
between the mitochondria and cytosol in proportion to mito-
chondrial membrane potential (Δψm) by virtue of its positive
charge. At low concentrations, the fluorescent intensity is a
simple function of dye concentration, which is in turn a di-
rect function of mitochondrial potential and associated
mitochondria function. After 12 h in SD TMRM fluorescence
was reduced in BMSCs, indicating a depolarization of the mi-
tochondrial membrane. Apelin-13 (0.1–5 nM) prevented the
SD-induced decreases in the TMRM fluorescent intensity in
a concentration-dependent manner (Fig. 3).Mitochondrial dysfunction provokes release of cyto-
chrome c from the mitochondria into the cytosol. Western
blot analysis revealed that exposure of BMSCs to SD induced
a significant increase in cytosolic cytochrome c levels, ac-
companied by a parallel decrease of cytochrome c in the mi-
tochondrial fraction (Figs. 4a and b). Apelin-13 (0.1–5 nM)
treatment concentration-dependently inhibited the cyto-
chrome c release from mitochondria (Figs. 4a and b).
Cytochrome c release leads to activation of caspase-3,
which is a key and executing step in the apoptosis process.
Western blotting showed that exposure to SD significantly
increased caspase-3 activation compared to the enzyme
level in control cells (Fig. 4c). Apelin-13 markedly inhibited
SD-induced activation of caspase-3, keeping the activity of
this enzyme near the control level (Fig. 4c).
Inhibitory effect of apelin-13 on ROS production
Dihydroethidium (DHE) is the chemically reduced form of the
DNA dye ethidium bromide. This probe is widely used in
Figure 2 Effect of Apelin-13 on cell viability. Apelin-13 was added into the culture media alone or co-applied with SD in order to
test its effect on cell viability of BMSCs. a. Trypan blue assessment indicated that apelin-13 alone was not toxic to cultured BMSCs.
Apelin-13 at 10 pM showed a trend of increasing the basal cell death, this phenomenon, however, was not seen with other concentra-
tions of apelin-13. We conclude that this insignificant trend was likely due to the variation of cell culture conditions. b. Hoechst 33342
nuclear staining examined morphological changes of BMSC nuclei. SD treatment (36 h) caused marked cell shrinkage and nuclear con-
densation (inset images), both are typical apoptotic morphology. Co-applied apelin-13 (5 nM) noticeably blocked the cell shrinkage
and nuclei condensation. c. Quantified data of trypan blue staining. The percentage of trypan blue positive cells vs. total cells was
calculated and shown in the bar graph. SD caused about 40–50% cell death, which was decreased by co-applied apelin-13 in a
concentration-dependent manner. The ERK1/2 blocker wortmannin (1 μM) and PI3K blocker UO126 (5 μM) reversed the apelin-13
effect, suggesting a mediator role of these signaling pathways (see Fig. 6 and corresponding text for more information). d. TUNEL
staining was used to further evaluate SD-induced cell death and the protective effect of apelin-13, both showed similar results as
seen in trypan blue experiments. e. Fluorescent imaging of BrdU (red) and Hoechst 33342 (blue) positive BMSCs. Cells were exposed
to apelin-13 (5 nM) for 24 h and BrdU was added during the last 8 h to label proliferating cells. f. Summarized data of the ratio of
BrdU-positive cells in control and apelin-13 treated cultures. N≥3 in each group. Mean±SEM, *Pb0.05 vs. SD.
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Figure 3 Effect of apelin-13 on the mitochondrial membrane potential. The mitochondrial membrane potential was measured
using TMRM fluorescence imaging in BMSCs. a. Control cells showed strong TMRM fluorescence indicative of normal membrane poten-
tial. After 12 h exposure to SD insult TMRM fluorescence decreased due to depolarization of the mitochondria. Apelin-13 (5 nM) added
into the serum free media retained the mitochondrial membrane potential. b. Quantified data showing the protective effect of ape-
lin-13 on the mitochondrial membrane potential. TMRM fluorescence decreased by 50% 12 h after SD while apelin-13 at 0.5 nM and
5 nM significantly reversed the loss of TMRM fluorescence. N=3 independent assays per group; mean±SEM, *Pb0.05 vs. SD group.
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excited red fluorescence in the nucleus. DHE fluorescent im-
aging was performed to detect ROS generation in BMSCs
under different conditions. After 12 h of SD insult, DHE
fluorescent-positive cells reached 38.5±0.8% of total cells.
This number of cells decreased to 26.0±0.6% by 0.5 nM
apelin-13 and 22.4±2.3% by 5 nM apelin-13, respectively
(Fig. 5).Roles of the MAPK/ERK1/2 and PI3K/Akt pathways in
mediating apelin-13 effects
The MAPK/ERK and PI3K/Akt signaling pathways mediate the
protective effects of apelin/APJ system in myocardial cells
and neuronal cells (Zeng et al., 2009, 2010). We therefore
investigated whether these pathways were involved in
the anti-apoptotic effects of apelin-13 in BMSCs. Western
blot analysis showed high levels of phospho-ERK1/2 in con-
trols and low levels in SD treated cells (Fig. 6). Apelin-13
increased ERK1/2 phosphorylation in a concentration-
dependent manner (Fig. 6a). To implicate ERK1/2 in
apelin-induced protection against SD, BMSCs were treated
with the specific blocker UO126 to inhibit this pathway.
Analysis by trypan blue and Hoechst staining showed that
UO126 (5 μM) attenuated the anti-apoptotic effect of
apelin-13 (Fig. 2c). In parallel with its effect on phosphoryla-
tion of ERK1/2, apelin-13 caused a significant increase in Akt
phosphorylation (Fig. 6b). Administration of the potent PI3K
inhibitor, wortmannin (1 μM), markedly blocked the anti-
apoptotic actions of apelin-13 (Fig. 2c).Discussion
Although BMSCs transplantation therapy has attracted con-
siderable interest in recent years for repairing ischemia-
damaged tissues in the heart and brain, its therapeutic ex-
ploitation has been limited by the fact that most of the
transplanted BMSCs do not survive, presumably die from ap-
optosis due to insults from the ischemic environment. The
present investigation demonstrates that apelin-13 can pro-
tect BMSCs from apoptotic cell death. We revealed that
apelin-13 acts on retaining the mitochondrial membrane po-
tential, preventing cytochrome c release from mitochon-
dria, reducing the production of reactive oxygen species,
and maintaining phosphorylation levels of ERK1/2 and Akt
signaling pathways. Our observations suggest that apelin-13
may be explored as a supplemental strategy to improve the
survival of BMSCs in transplantation therapy.
As an endogenous peptide, apelin has been shown to
be protective against multiple insults in cardiomyocytes
and neuronal cells (Simpkin et al., 2007; Zeng et al., 2009,
2010). Its effect on bone marrow stem cells has not been
studied prior to this investigation. We demonstrated that
BMSCs express the APJ receptor that is essential for the ape-
lin action. This is consistent with a very recent report show-
ing that the apelin-APJ pathway exists in BMSC-derived
cardiomyogenic cells (Gao et al., 2010). The physiological
function of endogenous apelin and APJ receptor in BMSCs is
not clear. In the above report, the authors suggest that
the expression of apelin-APJ pathway during differentiation
of BMSCs into cardiomyogenic cells may regulate myocardial
regeneration and functional recovery after BMSC
Figure 4 Effect of apelin-13 on cytochrome c release and
caspase-3 activation. Cytochrome c release and caspase-3 activa-
tion was tested 30 h after SD using Western blotting. a. Western
blotting results of cytochrome c content in the cytosolic fraction
of the cells. The cytochrome c level was high in SD treated cells.
Apelin-13 showed inhibitory effect on the cytochrome c increase,
especially at 5 nM concentration. b. Summary of normalized
values of cytochrome c levels in the mitochondrial and cytosolic
fractions of BMSCs. SD alone caused reduction of cytochrome c
in the mitochondria accompanied by a corresponding increase
in the cytoplasm. Apelin-13 reversed these apoptotic changes in
a concentration-dependent manner. c. Caspase-3 activation was
measured in cell lysates form different groups of cells. d. Quanti-
fied data of experiments in c. There was an increase in caspase-3
activity in SD treated BMSCs, Apelin-13 (1 nM) showed a significant
effect of blocking this caspase-3 activation. Mean±SEM. n=3
assays per group. *Pb0.05 vs SD group.
362 X. Zeng et al.transplantation. Our work endorses the idea that apelin is
also an important survival factor for BMSCs.
Apelin-13 showed a dose-dependent effect of antagonizing
apoptosis in BMSCs. Multiple criteria was applied to identify
the apoptotic nature of BMSC injury and the apelin-13 effect
following serum deprivation (SD). The SD insult has its limita-
tion; it does not mimic all aspects of an ischemic
attack. However, this in vitro cell death model has the advan-
tage of inducing typical “pure” apoptotic injury in neuronaland stem cell cultures, characterized by classical apoptotic
changes in cell morphology and biological/biochemical assays
(Yu et al., 1997; Valable et al., 2003). On the other hand,
many in vitro and in vivo insults, such as hypoxia in vitro and is-
chemia in vivo, trigger mixed cell death composed of both ne-
crosis and apoptosis (Xiao et al., 2002; Wei et al., 2004; Maurer
et al., 1999). Therefore, SD is useful for understanding the
cellular mechanism of the protective effect of apelin-13. We
showed that apelin-13 effectively prevented SD-induced mor-
phological alterations of cell shrinkage and nuclei condensa-
tion/fragmentation. Apelin-13 largely blocked several key
apoptotic steps in the mitochondria-dependent apoptosis cas-
cade. Cytochrome c is found in the mitochondria and released
into the cytoplasm after mitochondrial membrane depolariza-
tion, leading to the formation of apoptosome, activation of
caspase-3 and apoptosis (Kim et al., 2005). In our experiments,
DHE imaging for ROS production revealed that SD-induced ap-
optosis was accompanied with increased ROS production
while apelin-13 dose-dependently decreased DHE positive
cells. This event is likely associatedwith SD-inducedmitochon-
drial damage and the underlying apelin protective effect.
TMRM imaging was used to reveal mitochondrial potential
changes. Consistent with its effect on ROS production,
apelin-13 effectively prevented this mitochondrial depolariza-
tion and consequent events. Whether apelin-13 could affect
the apoptosis extrinsic pathway that is not mitochondria-
dependent remains to be tested. In our previous investigation,
we showed that apelin-13 not only blocked apoptosis in neuro-
nal cells, it also prevented NMDA receptor-mediated excito-
toxicity (Zeng et al., 2010). This apelin-13 action, however,
was not tested in the present study on non-differentiated
BMSCs because of the expected absence of glutamate recep-
tors in these cells. Since BMSCs can differentiate into neuronal
cells and this differentiationmay be a useful mechanism for re-
generation of CNS tissues, it may be necessary to understand
this protective mechanism in BMSC-derived neurons in a future
investigation. Different from the serum deprivation experi-
ment, we did not detect protective effect of apelin-13 against
OGD-induced cell death. This is likely due to the fact that con-
tinuous exposures to OGD trigger mainly necrotic but not apo-
ptotic cell death (Koh et al., 1995) and additionally implies
that, for BMSCs, apelin's protective effect was mainly from
its anti-apoptotic action which is the focus of this investigation
and likely to be a significant component of ischemic pathology.
Supporting the idea, previous work from our and other's groups
has demonstrated protective effects of apelin-13 against
ischemic damage in animal studies (Zeng et al., 2009, 2010;
Tao et al., 2011).
One of the major transduction pathways for apelin signal
depends on the interaction with a Gi-protein coupled to the
APJ receptor, independently of Ras protein; although depen-
dent on Protein Kinase C (PKC) (Masri et al., 2005). In addition
to the adenyl cyclase inhibition pathway, apelin activates ERK
pathways through a PTX (pertussis toxin) sensitive Gαi protein,
in a PKC-dependent process (Masri et al., 2005). Endothelial
cell proliferation control is activated by apelin through two
mechanisms: one is ERK-dependent and the other is PI3K-
dependent (Masri et al., 2004). Some of these events may be
conducive to enhance cell survival. Our current data demon-
strated that apelin/APJ exerts its anti-apoptotic effects in
BMSCs through ERK and Akt pathways. We showed that inhibi-
tion of PI3K with the specific blocker wortmannin or blocking
Figure 5 Effect of apelin-13 on reactive oxygen species production of apoptotic BMSCs. Detection of ROS production in rat BMSCs
using DHE fluorescence imaging. Cells were incubated with DHE for 5 min following 12 h SD treatment. Fluorescence was captured
then quantitated for the total cells and DHE positive cells which displayed red fluorescence nuclear. a. DHE images showing the fluo-
rescent images of control, SD-treated and SD plus apelin-13 (5 nM) cells. The increase fluorescent intensity in SD-treated cells
indicted increased ROS production. b. Summary of experiments with different concentrations of apelin-13. Serum deprivation
increased ROS generation while apelin-13 concentration-dependently decreased its production. Bars show the average percent of
DHE fluorescent positive cells to total cells. N=3 assays; mean±SEM, *Pb0.05.
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apelin-13. These observations are consistent with previous in-
vestigations on cardiomyocytes and neuronal cells from our
and other groups (Zeng et al., 2009, 2010; Masri et al., 2004;
O'Donnell et al., 2007). In our experiments, apelin-13 did not
stimulate proliferation of BMSCs. The regulatory mechanism
for proliferation of BMSCs is not well defined. Our data implies
that proliferation of BMSCs is not under direct regulation of
apelin/APJ signaling.
In summary, we have presented novel data showing
protective effects of apelin-13 against apoptosis in BMSCs.
Apelin-13 effectively prevents several mitochondria associ-
ated apoptotic events and helps to regulate phosphorylation
of the MAPK/ERK1/2 and PI3K/Akt pathways. It is feasible
that apelin-13 conjugated with the APJ receptor can exert
its pro-survival actions on BMSCs after transplantation. If
so, apelin-13 may be applied to promote cell survival and
therapeutic potential of stem cell therapy for ischemia re-
lated disorders such as heart ischemia and ischemic stroke.Materials and methods
Rat BMSC cultures
BMSCs were isolated from Wistar rats as previously described
(Hu et al., 2008). In brief, BMSCs were obtained from the
femoral and tibial bones of rats. Cells were flushed fromthe femurs and tibias of rats using a 25-guage needle. Mono-
nuclear cells were suspended in Dulbecco's modified Eagle's
medium supplemented with 10% fetal bovine serum and plat-
ed in flasks. Cultures were maintained at 37 °C in a humidi-
fied atmosphere containing 5% carbon dioxide. After 24 h,
non-adherent cells were discarded, and adherent cells
were washed three times with phosphate-buffered saline
solution (PBS). Fresh complete medium was added and
replaced every 4 days. Each primary culture was sub-
cultured 1:2 when BMSCs grew to 80% confluency.Bone marrow mesenchymal stem cell
characterization
All cells used in assays were of passage 3 to 5. By the third
passage, a homogenous population of fibroblast-like cells
was obtained. To prevent hematopoietic cell contamination,
which might be present in earlier passages, or the presence
of senescent or differentiating BMSC in later passages, we
used cells between passages three and five throughout the
study. BMSCs used in our investigation have been fully char-
acterized according to cell surface markers and multipotent
differentiation assays; these data were reported in previous
papers (Hu et al., 2008; Hu et al., n.a.). Briefly, flow cyto-
metric analysis confirmed that these cells expressed CD73,
CD90 and CD105 surface markers, but were CD34 and CD45
negative (Hu et al., 2008). The lack of expression of CD34
Figure 6 Effect of apelin-13 on ERK1/2 and Akt signaling
pathways. Western blotting was performed to assess protein
levels of ERK1/2 and Akt in BMSCs after 6 h treatment with SD
and the effect of co-applied apelin-13. a. The phosphor-ERK1/
2 (p-ERK) and total ERK 1/2 (t-ERK) levels in BMSCs undergoing
apoptosis and in the presence of different concentrations of
apelin-13 (0.1 to 5.0 nM). The bar graph summarizes the densi-
tometry of Western blotting, showing a reduction in the ratio
of p-ERK/t-ERK in SD only cells and a concentration-dependent
reverse of this ratio by apelin-13. b. Western blotting of
phosphor-Akt (p-Akt) and total Akt (t-Akt) normalized to α-
tubulin in BMSCs subjected to different treatments. Wortmannin
was added to block PI3K that is upstream of Akt signaling.
The bar graph of densitometry measurement shows reduction
of p-Akt/t-Akt ratio (each level was normalized to α-tubulin),
while apelin-13 at 0.5 and 5 nM prevented the p-Akt reduction.
The apelin-13 effect was blocked by Wortmannin. N=3 assays
in each group; mean±SEM; *Pb0.05 vs. SD group.
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hematopoietic stem cells. We have tested the multipotency
of these cells as suggested by Dominici et al. (2006). The dif-
ferentiation potential of these cells for becoming osteocyte
and adipogenic cell phenotypes was confirmed (Hu et al.,
n.a.). The surface markers and multipotency property of
these cells were thus highly consistent with the characteris-
tics of bone marrow mesenchymal cells (Dominici et al.,
2006).Detection of APJ expression on BMSCs
To confirm that APJ was expressed in our BMSCs, we used RT-
PCR, immunofluorescent staining, and Western blot to detect
APJ expression in these cells. Briefly, total RNA was extracted
from cultured BMSCs using the RNAeasy Mini prep kit (Qiagen
Inc, Valencia, CA) according to the manufacturer's instruc-
tions. Promega reverse transcription system (Promega Corp.,
Madison, WI) was used to reverse transcribe total RNA (2 μg)
into first strand cDNA with Oligo (dT)18 primer. After that,
the total length of rat APJ primers forward 5′ ATGGAAGAT-
GATGGTTACA 3′ and reverse 5′ GTCCACAAGGGTTTCTTGGC
3′ were used to amplify rat APJ. Taq4 polymerase was used
with an initial denaturation at 94 °C for 5 min followed by 30
cycles of 95 °C for 45 s, 54 °C for 45 s, 72 °C for 1.5 min and
a final extension step at 72 °C for 10 min. PCR products were
ran and imaged on an 1.0% agarose gels stained with ethidium
bromide. Expected fragment sizes of 1121 bp, for a plasmid
template from PcDNA3.1+/APJ was used as a positive control.
Human embryonic kidney HEK293 cells were used as a negative
control for the primers.
For Immunofluorescence staining, cultured BMSCs were
fixed with 100% methanol for 5 min, and subjected to per-
meabilization with 0.2% triton X-100. After blocking with
1% fish gel in PBS for 1 h at room temperature, a primary
antibody was added and incubated at 4 °C overnight. The
primary antibody anti-APJ (rabbit anti-APJ polyclonal anti-
body; APJR-1H-300) was purchased from Santa Cruz (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) and the anti-
CD90 antibody was purchased from Abcam (Cambridge,
MA). The antibodies were diluted to 2 μg/ml in PBS. The
next day, the dishes were balanced at room temperature
for 1 h and washed with PBS three times, then incubated
for 2 h at room temperature in PBS containing secondary an-
tibody: donkey anti-Rabbit IgG polyclonal antibody (488 con-
jugate, 500 μg; Chemicon/Millpore Corporation, Billerica,
MA) diluted to 1 μg/ml. After washing with PBS three times
Hoechst 33342 (Molecular Probes, Carlsbad, CA) at 1:20,000
in PBS was added and incubated for 5 min followed by three
PBS washes. Coverslips were mounted on the bottom of the
dishes in VECTASHIELD Mounting Medium (10 ml; Vector Lab-
oratories, Inc., Burlingame, CA). Micrographs were captured
on an Olympus IX61 microscope at 20× magnification.
To detect APJ expression in BMSCs, 40 μg of protein har-
vested from cultured BMSCs was subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis, the primary an-
tibody was the same antibody used in staining, the secondary
antibody used was alkaline phosphatase — conjugated (Cell
Signaling Technology, Danvers, MA) at a 1:2000 dilution,
and the membranes were developed by the addition
of BCIP/NBT solution (Sigma-Aldrich, St. Louis, MO).
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We tested potential toxicity of apelin at different concen-
trations on cultured rat BMSCs. BMSCs were incubated
with apelin-13 (synthesized Apelin-13 trifluoroacetate salt,
≥95% purity; Sigma-Aldrich) in culture medium for 36 h.
According to the material information provided by the man-
ufacturer, the compound does not contain bacteria endotox-
in or other hazardous substance. Trypan blue was added into
the medium then incubated at 37 °C for 15 min before phase
contrast graphs were taken by a microscope and trypan blue
positive cells were counted. Five fields were randomly
selected for every dish and at least three dishes were
counted for every concentration.
Serum deprivation-induced cell death of rat BMSCs
BMSCs were exposed to control, serum-free medium, and
serum-free plus apelin-13 media for 36 h. Cell morphology
was photographed using a phase-contrast microscope
(Nikon Corp. New York, NY). Nuclear condensation and frag-
mentation was assessed using chromatin dye Hoechst 33342
as previously described. Apoptotic cells were characterized
by morphological alteration such as condensed nuclei and
cell shrinkage. Cell death was analyzed using Trypan
blue staining and Terminal deoxynucleotidyltransferase-
mediated DUTP-biotin nick end labeling (TUNEL) staining. A
TUNEL staining kit, DeadEnd™ Fluorometric TUNEL System
(Promega Corp.) was used for TUNEL staining according to
the manufacturer's instruction. Briefly, cells were fixed by
10% formalin, cell permeabilization was done with 0.2% Tri-
ton X-100, equilibrated with equilibration Buffer for 10 min
and incubated in rTdT Incubation Buffer for 60 min at
37 °C, then in 2× SSC for 15 min at room temperature and
incubated with Hoechst 33342 (1:20,000) for 5 min. The
dish was mounted in VECTASHIELD Mounting Medium (Vector
Laboratories, Inc.).
Cell counting was performed in five non-overlapping fields
captured on an Olympus IX61 microscope at 20× magnifica-
tion. The percentage of Trypan blue positive and TUNEL pos-
itive cells vs. total cells was counted and calculated. At least
1000 BMSCs were counted for every dish and averaged, at
least three dishes were counted for every group.
Oxygen-glucose deprivation induced BMSC cell
death
Oxygen and glucose deprivation (OGD) was employed to in-
duce cell death in BMSC cultures. BMSC cultures of passages
3 to 5 were plated in 96 well plates and allowed to attach
overnight in standard culture media. To initiate OGD condi-
tion, cells were washed in PBS twice and then incubated in
a physiological buffer solution lacking glucose (120 mM
NaCl, 25 mM Tris–HCl, 5.4 mM KCl, 1.8 mM CaCl2, pH to 7.4
with NaOH). Cells were incubated in a calibrated hypoxia
chamber perfused with 5% CO2 and balanced Nitrogen for a
final ambient oxygen level of 0.2%. Oxygen level was estab-
lished, maintained and monitored by the ProOx 360 sensor
(Biospherix, NY). After specified duration of OGD exposure,
cells were “reperfused” by return to the normal 5% CO2 incu-
bator and normal oxygenated culture media. To test theeffect of Apelin-13 on OGD-induced cell death, Apelin-13
was co-applied during the OGD. Apelin-13 was also re-
applied upon reperfusion. Cell viability assay was initiated
by adding MTT (0.5 mg/ml; Thiazolyl Blue Tetrazolium Bro-
mide) 24 h after the onset of OGD followed by solubilization
(20% SDS in 0.1 N HCl) overnight before measuring the MTT
reaction in a plate reader. Cell viability was normalized to
control non-OGD treated parallel cultures.
Proliferation assay of BMSCs
BMSC cells of P2–P5 were plated in 35-mm Petri dishes, 5 nM
apelin was added to treat cells for 24 h. BrdU (10 Um) was
added during the last 8 h to label proliferating cells. After
BrdU incorporation, cells were fixed by 4% paraformalde-
hyde for 15 min and followed by BrdU immunostaining. Brief-
ly, cells were treated with 2 N HCl for 1 h, followed by
45 min in 0.2% Triton-X 100. After 1% fish gel blocking for
1 h, rat anti-BrdU antibody (1:400; Abcam, Cambridge, UK)
was applied overnight. Cells were incubated with secondary
antibody Cy3-conjugated anti-rat IgG (1:400; Invitrogen)
for 1 h. Staining was visualized by fluorescent microscopy
(BX61; Olympus, Tokyo, Japan). Numbers of BrdU positive
cells were calculated by counting 6 random fields in each
dish with three dishes per group. The results are presented
as percentage of BrdU-positive cells per total cells (Hoechst
33342 staining).
Analysis of mitochondrial membrane potential and
cyochrome c release
The mitochondrial membrane potential dye, tetramethylr-
hodamine methyl ester (TMRM; Invitrogen) was loaded for
30 min at 37 °C in the dark, the cells were washed in fresh
media, and treated with SD with or without apelin-13 for
12 h. TMRM was excited at 543 nM, 25% of the dye was pre-
sent in the buffer during the entire course of the experi-
ment. TMRM fluorescence was then measured under a
fluorescence microscope. The quantification of the results
was taken with the Image J software (NIH, Maryland, MD).
For the analysis of cytochrome c release from mitochon-
dria, mitochondrial and cytosol proteins were extracted
with the Mitochondria Isolation kit (Pierce, Rockford, IL)
according to the manufacturer's protocols. Briefly, cells
were incubated with 1.0 ml Cytosol Extraction Buffer Mix
for 10 min, and homogenized using an ice-cold Dounce tissue
grinder. The homogenates were centrifuged at 700 g and
then the supernatants were further centrifuged at 10,000 g
for 30 min at 4 °C. The cytosolic supernatants were dec-
anted and the pellets were resuspended in 0.1 ml mitochon-
drial extraction buffer mix. Both the mitochondrial and
cytosolic fractions were subjected to standard Western blot-
ting and probed with a mouse monoclonal anti-rat cyto-
chrome c antibody.
Measurement of intracellular reactive oxygen
species (ROS)
ROS production was measured using the specific dye dihy-
droethidium (DHE; Molecular Probes) prepared in DMSO.
The stock solutions were diluted in tissue culture media to
366 X. Zeng et al.the desired concentrations. Cells were incubated with
5 μmol/l DHE. Briefly, after experimental treatments, cells
were incubated with 5 μmol/l DHE and 1:10,000 Hoechst
33342 in culture media for 5 min at 37 °C in the dark, and
then fluorescent images were taken to count the percentage
of DHE positive nuclear cells. Three independent experi-
ments were performed.Protein extraction and Western blot analysis
For analysis of cellular protein levels, cells were rinsed twice
with ice-cold PBS and lysed in ice-cold lysis buffer (20 mM
Tris at pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
TritonX-100, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerol glycerolphosphate, 1 mM Na3VO4, 1 mM PMSF, and
10 μg/ml each of Leupeptin, Aprotinin, and Pepstatin) for
30 min. Cell lysates were centrifuged at 13,000 g for 10 min
at 4 °C and the protein concentration was determined by
the BCA assay. Equal amounts of protein was determined
and loaded per lane. The protein samples were mixed with
5× SDS sample buffer, boiled for 5 min and separated on
6%–18% SDS-PAGE gels before transferring the proteins
onto a PVDF membrane by humid transfer. After blocking
in 5% BSA for 1 h, membranes were rinsed and incubated
overnight at 4 °C with the appropriate diluted primary anti-
body in 5% BSA, 1× TBS, and 0.1% Tween-20 (TBS/T), with
gentle shaking. Excess antibody was removed by washing
the membrane in TBS/T and subsequently incubated for 1 h
with AP-conjugated secondary antibody at room tempera-
ture. After further washing in TBS/T, bands were developed
by the addition of BCIP/NBT solution (Sigma-Aldrich). The
membrane was scanned and analyzed by densitometry
using Adobe Photoshop (Adobe Systems Inc., San Jose, CA)
and Image J. Signal intensities of phosphorylated proteins
were normalized to α-tubulin.Statistical analysis
Data expressed as mean±SEM. Differences among groups
were tested by one-way ANOVA. Comparisons between
two groups were evaluated using LSD (least significant dif-
ference) t test. A value of pb0.05 was considered as signifi-
cantly different.Acknowledgments
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